Terms: = Ovarian cancer AND RUNX1T1, ENSG00000079102, 862 AND Treatment
15 results:
1. The Gustave Roussy immune score as a novel scoring system for predicting platinum resistance in advanced high-grade serous ovarian cancer.
Nie X; Xu T; Zhang L; Cheng W
Eur J Obstet Gynecol Reprod Biol; 2024 Mar; 294():97-104. PubMed ID: 38219610
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Frenel JS; Kim JW; Aryal N; Asher R; Berton D; Vidal L; Pautier P; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Colombo N; Park-Simon TW; Tamura K; Sonke GS; Freimund AE; Lee CK; Pujade-Lauraine E
Ann Oncol; 2022 Oct; 33(10):1021-1028. PubMed ID: 35772665
[TBL] [Abstract] [Full Text] [Related]
3. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced ovarian/Tubal/Peritoneal cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.
Copeland LJ; Brady MF; Burger RA; Rodgers WH; Huang HQ; Cella D; O'Malley DM; Street DG; Tewari KS; Bender DP; Morris RT; Lowery WJ; Miller DS; Dewdney SB; Spirtos NM; Lele SB; Guntupalli S; Ueland FR; Glaser GE; Mannel RS; DiSaia PJ
J Clin Oncol; 2022 Dec; 40(35):4119-4128. PubMed ID: 35759733
[TBL] [Abstract] [Full Text] [Related]
4. A prognostic model of patients with ovarian mucinous adenocarcinoma: a population-based analysis.
Yang L; Yu J; Zhang S; Shan Y; Li Y; Xu L; Zhang J; Zhang J
J Ovarian Res; 2022 Feb; 15(1):26. PubMed ID: 35168642
[TBL] [Abstract] [Full Text] [Related]
5. Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer.
Tasaka N; Minaguchi T; Hosokawa Y; Takao W; Itagaki H; Nishida K; Akiyama A; Shikama A; Ochi H; Satoh T
J Obstet Gynaecol Res; 2020 May; 46(5):765-773. PubMed ID: 32147891
[TBL] [Abstract] [Full Text] [Related]
6. Current Possibilities of Gynecologic cancer treatment with the Use of Immune Checkpoint Inhibitors.
Grywalska E; Sobstyl M; Putowski L; Roliński J
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547532
[TBL] [Abstract] [Full Text] [Related]
7. Model for Prediction of Optimal Debulking of Epithelial ovarian cancer.
Arab M; Jamdar F; Sadat Hosseini M; Ghodssi- Ghasemabadi R; Farzaneh F; Ashrafganjoei T
Asian Pac J Cancer Prev; 2018 May; 19(5):1319-1324. PubMed ID: 29802693
[TBL] [Abstract] [Full Text] [Related]
8. Coumestrol Inhibits Proliferation and Migration of Prostate cancer Cells by Regulating AKT, ERK1/2, and JNK MAPK Cell Signaling Cascades.
Lim W; Jeong M; Bazer FW; Song G
J Cell Physiol; 2017 Apr; 232(4):862-871. PubMed ID: 27431052
[TBL] [Abstract] [Full Text] [Related]
9. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory ovarian cancer.
Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
[TBL] [Abstract] [Full Text] [Related]
10. Preoperative fluorine 18 fluorodeoxyglucose tumoral uptake ratio between upper and lower abdomen in primary advanced-stage ovarian cancer.
Shim SH; Kim DY; Seo MJ; Lee SW; Park JY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2013 Oct; 23(8):1383-92. PubMed ID: 24257552
[TBL] [Abstract] [Full Text] [Related]
11. Bowel obstruction in elderly ovarian cancer patients: a population-based study.
Mooney SJ; Winner M; Hershman DL; Wright JD; Feingold DL; Allendorf JD; Neugut AI
Gynecol Oncol; 2013 Apr; 129(1):107-12. PubMed ID: 23274561
[TBL] [Abstract] [Full Text] [Related]
12. Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, runx1t1 in ovarian cancer.
Yeh KT; Chen TH; Yang HW; Chou JL; Chen LY; Yeh CM; Chen YH; Lin RI; Su HY; Chen GC; Deatherage DE; Huang YW; Yan PS; Lin HJ; Nephew KP; Huang TH; Lai HC; Chan MW
Epigenetics; 2011 Jun; 6(6):727-39. PubMed ID: 21540640
[TBL] [Abstract] [Full Text] [Related]
13. Potential clinical applications of epothilones: a review of phase II studies.
Larkin JM; Kaye SB
Ann Oncol; 2007 Jul; 18 Suppl 5():v28-34. PubMed ID: 17656559
[TBL] [Abstract] [Full Text] [Related]
14. Epothilones in the treatment of cancer.
Larkin JM; Kaye SB
Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
[TBL] [Abstract] [Full Text] [Related]
15. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer.
Polyzos A; Tsavaris N; Kosmas C; Giannikos L; Katsikas M; Kalahanis N; Karatzas G; Christodoulou K; Giannakopoulos K; Stamatiadis D; Katsilambros N
Oncology; 1999; 56(4):291-6. PubMed ID: 10343192
[TBL] [Abstract] [Full Text] [Related]
